N,N'-bis[3-(methylamino)propyl]but-2-yne-1,4-diamine

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N,N'-bis[3-(methylamino)propyl]but-2-yne-1,4-diamine
• 化学式: C₁₂H₂₆N₄
• 分子量: 226.36
• InChiKey: AUMZCBFCTWBSJE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  16
• 可旋转键数：
  10
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  48.1
• 氢给体数：
  4
• 氢受体数：
  4

文献信息

• NOVEL POLYAMINE ANALOG CONJUGATES AND QUINONE CONJUGATES AS THERAPIES FOR CANCERS AND PROSTATE DISEASES
  申请人：Frydman Benjamin

  公开号：US20080194697A1

  公开（公告）日：2008-08-14

  Peptide conjugates in which cytostatic and cytostatic agents, such as polyamine analogs or naphthoquinones, are conjugated to a polypeptide recognized and cleaved by enzymes such as prostate-specific antigen (PSA) and cathepsin B are provided, as well as compositions comprising these conjugates. Methods of using these conjugates in the treatment of prostate diseases are also provided.

  提供了肽共轭物，其中细胞生长抑制剂和细胞毒剂，如多胺类似物或萘醌，与多肽共轭，并被酶如前列腺特异性抗原（PSA）和半胱氨酸蛋白酶B识别和剪切，以及包含这些共轭物的组合物。还提供了使用这些共轭物治疗前列腺疾病的方法。
• Treatment and prevention of vascular hyperplasia using polyamine and polyamine analog compounds
  申请人：Marton J. Laurence

  公开号：US20070232677A1

  公开（公告）日：2007-10-04

  This disclosure relates to methods of inhibiting vascular hyperplasia using polyamines, polyamine analogs, and conformationally restricted polyamine analogs, or a conjugate of a polyamine, polyamine analog, or conformationally restricted polyamine analog. Polyamines, polyamine analogs, conformationally restricted polyamine analogs, and conjugates thereof are useful in reducing stenosis and restenosis of blood vessels and grafts.

  本公开涉及使用多胺，多胺类似物和构象限制多胺类似物或多胺，多胺类似物或构象限制多胺类似物的共轭物来抑制血管增生的方法。多胺，多胺类似物，构象限制多胺类似物及其共轭物在减少血管和移植物的狭窄和再狭窄方面非常有用。
• COMPOSITIONS AND METHODS FOR TRANSPORT OF MOLECULES WITH ENHANCED RELEASE PROPERTIES ACROSS BIOLOGICAL BARRIERS
  申请人：Wender Paul A

  公开号：US20100255499A1

  公开（公告）日：2010-10-07

  Conjugates of a cargo molecule with a transporter molecule are disclosed, where the cargo molecule and the transporter molecule are linked covalently by a releasable linker. The cargo of the conjugate can be a biologically active agent or a reporter molecule. The transporter modulates the transport of the cargo across a biological barrier (e.g., a cell membrane) compared to the transport of the unconjugated cargo. Releasable linkers suitable for rapid and facile conjugation to various types of cargo and transporters are also disclosed, along with methods for using the linkers in the synthesis of conjugates.

  本发明公开了一种货物分子与运输蛋白分子的共轭体，其中货物分子和运输蛋白分子通过可释放的连接剂共价连接。共轭体的货物可以是生物活性剂或报告分子。与未共轭货物的运输相比，运输蛋白调节货物通过生物屏障（例如细胞膜）的运输。还公开了适用于快速和容易地与各种类型的货物和运输蛋白共轭的可释放连接剂，以及使用连接剂合成共轭体的方法。
• Polyamine Analogs as Modulators of Cell Migration and Cell Motility
  申请人：Marton Laurence J.

  公开号：US20090143456A1

  公开（公告）日：2009-06-04

  This disclosure relates to methods of inhibiting cell motility or cell migration, and of treating diseases involving cell migration or cell motility, using polyamine analogs, such as conformationally restricted polyamine analogs. The diseases to be treated include immune disorders, inflammatory conditions, infection, abnormal immune responses, undesired angiogenesis, tumor cell metastasis or invasion, atherosclerosis, vascular graft occlusion, transplant rejection, other complications of transplants, glomerulonephritis, arthritis, inflammatory responses subsequent to stroke or ischemia, and asthma.

  本披露涉及使用聚胺类似物，如构象限制聚胺类似物，抑制细胞运动或细胞迁移的方法，以及治疗涉及细胞迁移或细胞运动的疾病。要治疗的疾病包括免疫障碍，炎症状况，感染，异常免疫反应，不良血管生成，肿瘤细胞转移或侵袭，动脉硬化，血管移植闭塞，移植排斥，移植其他并发症，肾小球肾炎，关节炎，中风或缺血后的炎症反应以及哮喘。
• MITOGUAZONE FOR PREVENTING THE RELAPSE OR THE PROGRESSION OF MULTIPLE SCLEROSIS
  申请人：Pathologica LLC

  公开号：EP3831372A1

  公开（公告）日：2021-06-09

  Disclosed herein are new oral pharmaceutical compositions of SAMDC inhibitors, polyamine analogs, and polyamine biosynthesis inhibitors, and their application for the treatment of conditions including demyelinating diseases, autoimmune disorders affecting the nervous system, and other neurodegenerative conditions.

  本文公开了SAMDC抑制剂、多胺类似物和多胺生物合成抑制剂的新型口服药物组合物，以及它们在治疗脱髓鞘疾病、影响神经系统的自身免疫性疾病和其他神经退行性疾病等疾病中的应用。